Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,282
Out of 5,182 analysts
21
Total ratings
25%
Success rate
34.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $5.30 | +88.68% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $18.05 | +49.58% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $98 | $7.88 | +1,143.65% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $26.99 | +18.56% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $2,200 | $4.54 | +48,321.89% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.01 | +199.00% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $23.71 | -66.26% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.30
Upside: +88.68%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $18.05
Upside: +49.58%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $98
Current: $7.88
Upside: +1,143.65%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $26.99
Upside: +18.56%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $2,200
Current: $4.54
Upside: +48,321.89%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.01
Upside: +199.00%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $23.71
Upside: -66.26%